EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 120 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2015. The put-call ratio across all filers is 4.58 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $2,944,000 | -31.7% | 37,106 | -23.7% | 0.39% | -30.7% |
| Q4 2015 | $4,311,000 | +39.2% | 48,624 | +16.2% | 0.56% | +14.9% |
| Q3 2015 | $3,098,000 | -50.6% | 41,844 | -46.1% | 0.49% | -33.1% |
| Q2 2015 | $6,275,000 | -3.2% | 77,602 | -49.8% | 0.73% | -2.0% |
| Q1 2015 | $6,482,000 | – | 154,734 | – | 0.75% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |